Vitality Watch

⚠ Evidence note: Human outcome data on longevity interventions is limited; most claims rest on surrogate markers or animal models. Nothing here is medical advice.

Mentioned 1× · first seen 16-nov-2026 · last seen 16-nov-2026

Klotho Protein and Gene Therapies

Current understanding

To be populated as evidence accumulates.

Evidence log

  • 2026-11-12 — Phase I Trial of a Single Administration of aKLmRNA-Mediated Protein Replacement Therapy: [mechanism-plausible — efficacy rationale only, not randomized human evidence] An open-label Phase I protocol at GARM Próspera describes a single intravenous AKL003 alpha-Klotho mRNA infusion in 20 planned healthy participants, assessing safety and exploratory aging markers including DNA methylation; the finding reports no outcome results and does not establish safety, healthspan benefit, or lifespan extension. [mechanism-plausible] (novelty: 4)

Open questions

Related

Contributing findings

clinicaltrials trial early mechanism-plausible
Phase I Trial of a Single Administration of aKLmRNA-Mediated Protein Replacement Therapy
12-nov-2026 novelty 4 per-area 4 strengthens

build build 880 · 2bcef25 · 2026-11-18